RNS - Appointment of Joint Broker

Blog image

Alderley Park, 1 November 2021  

BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that it has appointed Panmure Gordon (UK) Limited to act as Joint Broker to the Company alongside SP Angel Corporate Finance LLP with immediate effect.

Read RNS Here

newsletter

Contact BivictriX

Please submit the form below and we shall be in touch
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
AntibodyPatient Image